Drugs from

natural fungi

Unlocking the potential of the nature

Between 1983 and 1997, 39% of all new approved drugs and 43% of antibacterial and anticancer drugs were from either natural products or derived from natural products.

The Fungi kingdom is a largely untapped source of chemical diversity.
Chances to find unidentified fungal species and novel bioactive fungal products are still high.


Mushrooms and innovation

Recent scientific studies have highlighted the antimicrobial activity of fungal extracts and their potential as sources for drug discovery.  Cases like Antroquinonol (isolated from fungus Antrodia camphorata) in phase 2 trial for the treatment of metastatic pancreatic cancer and COVID-19 showcase the potential of fungi in drug discovery.

The world of fungi also presents a valuable source of innovation for the early discovery of drugs targeting multidrug-resistant bacterial strains.

At Hifas Biologics, we approach the antimicrobial resistance need by the following strategic focus:


Design and optimization of the mycotheque/activotheque, including:

  • New authochtonous mushrooms strains (150 strains today)
  • New conservation methods
  • Extraction and fractionation techniques


Network of strategic partners for Open Innovation Drug Discovery processes

Including scientific institutions, universities and CROs:

  • High Throughput Screening (HTS) / Pharmacology
  • Chemical profiling and active principles isolation
  • In vitro functional assays
  • Chemical synthesis
  • Scientific Committee


Generation of Intellectual Property (IP)

Intellectual Property (IP) generation is a fundamental aspect at Hifas Biologics, as it allows us to protect our innovations, establish a competitive advantage, and foster collaboration and innovation in the field of research on new drugs derived from fungi.

Be part of the company
Fleming would’ve invested in